Compare ILMN & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILMN | LII |
|---|---|---|
| Founded | 1998 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9B | 17.4B |
| IPO Year | 2000 | 1999 |
| Metric | ILMN | LII |
|---|---|---|
| Price | $135.03 | $504.69 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 15 | 12 |
| Target Price | $114.93 | ★ $603.36 |
| AVG Volume (30 Days) | ★ 1.6M | 472.7K |
| Earning Date | 10-30-2025 | 01-28-2026 |
| Dividend Yield | N/A | ★ 1.03% |
| EPS Growth | N/A | ★ 12.46 |
| EPS | 4.46 | ★ 23.67 |
| Revenue | $4,288,000,000.00 | ★ $5,345,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.08 | $7.34 |
| P/E Ratio | $30.24 | ★ $21.37 |
| Revenue Growth | N/A | ★ 3.77 |
| 52 Week Low | $68.70 | $443.19 |
| 52 Week High | $153.06 | $689.44 |
| Indicator | ILMN | LII |
|---|---|---|
| Relative Strength Index (RSI) | 69.62 | 54.60 |
| Support Level | $126.44 | $497.54 |
| Resistance Level | $129.72 | $525.00 |
| Average True Range (ATR) | 3.59 | 13.75 |
| MACD | 0.08 | 4.10 |
| Stochastic Oscillator | 85.06 | 67.70 |
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.